The present invention provides, among other things, a novel class of cationic lipid compounds (e.g., cationic lipids having a structure according to Formula (I)) for
in vivo delivery of therapeutic agents, such as nucleic acids. It is contemplated that these compounds are capable of highly effective
in vivo delivery while maintaining a favorable
toxicity profile.